ReviewNature reviews. Cardiology2014
Does cardiovascular protection translate into renal protection?
Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets.Frontiers in physiology · 2021Review
- Article
- Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.European heart journal · 2019Article
- Global cardiovascular protection in chronic kidney disease.Nature reviews. Cardiology · 2016Review
- Glucose Homeostasis and Cardiovascular Alterations in Diabetes.Comprehensive Physiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and renal disease often have similar origins and shared risk factors. With the progression of chronic kidney disease (CKD), additional risk factors develop, contributing to the evolution of both diseases. Progression of CKD has been primarily investigated in patients with established diabetic nephropathy and severely increased albuminuria, in cohorts smaller than those necessary for studies of cardiovascular outcomes. Consequently, simultaneous cardiovascular and renal protection was not demonstrated clearly in these studies. Nevertheless, data from some clinical trials in the field of arterial hypertension have demonstrated that cardiovascular and renal protection can be attained using the same therapy. Further investigation on factors that promote rapid progression of cardiovascular disease and CKD should result in new therapies to improve the outcome of patients presenting with both diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.